Enalapril and losartan reduce sympathetic hyperactivity in patients with chronic renal failure

Journal of the American Society of Nephrology

Volumn 14, Issue 2, 2003, Pages 425-430

  Klein, Inge H H T ^a   Ligtenberg, Gerry ^a   Oey, P Liam ^a   Koomans, Hein A ^a   Blankestijn, Peter J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; LOSARTAN; RENIN;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE REGULATION; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; HUMAN; HYPERTENSION; MALE; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYMPATHETIC TONE;

EID: 0037304676     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ASN.0000045049.72965.B7     Document Type: Article

References (30)

1. Augustyniak RA, Tuncel M, Zhang W, Toto KD, Victor RG: Sympathetic overactivity as a cause of hypertension in chronic renal failure. J Hypertens 20: 3-9, 2002
2. Matsukawa T, Gotoh E, Minamisawa K, Kihara M, Ueda S, Shionoiri H, Ishii M: Effects of intravenous infusions of angiotensin II on muscle sympathetic nerve activity in humans. Am J Physiol 261: R690-R696, 1991
3. Ligtenberg G, Blankestijn PJ, Oey PL, Klein IHH, Dijkhorst-Oei LT, Boomsma F, Wieneke GH, van Huffelen AC, Koomans HA: Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure. N Engl J Med 340: 1321-1328, 1999
4. Mancia G, Grassi G, Giannattasio C, Seravalle G: Sympathetic activation in the pathogenesis of hypertension and progression of organ damage. Hypertension 34: 724-728, 1999
5. Gansevoort RT, de Zeeuw D, Shahinfar S, Redfield A, De Jong PE: Effects of the angiotensin II antagonist losartan in hypertensive patients with renal disease. J Hypertens 12[suppl 12]: S37-S42, 1994
6. Toto R, Shultz P, Raij L, Mitchell H, Shaw W, Ramjit D, Toh J, Shahinfar S. Efficacy and tolerability of losartan in hypertensive patients with renal impairment. Hypertension 31: 684-691, 1998
7. Schulz E, Bech JN, Pedersen EB, Müller GA: A randomized, double-blind, parallel study on the safety and antihypertensive efficacy of losartan compared to captopril in patients with mild to moderate hypertension and impaired renal function. Nephrol Dial Transplant 14[suppl 4]: 27-28, 1999
8. Burnier M, Brunner HR: Angiotensin II receptor antagonists. Lancet 355: 637-45, 2000
9. Vaughan D: Pharmacology of ACE inhibitors versus AT1 blockers. Can J Cardiol 16[Suppl E]: 36E-40E, 2000
10. Hollenberg NK, Fisher ND, Price DA: Pathways for angiotensin II generation in intact human tissue: evidence from comparative pharmacological interruption of the renin system. Hypertension 32: 387-392, 1998
11. Bos WJ, Imholz BP, van Goudoever, Wesseling KH, van Montfrans GA: The reliability of noninvasive continuous finger blood pressure measurement in patients with both hypertension and vascular disease. Am J Hypertens 5: 529-535, 1992
12. Vallbo AB, Hagbarth KE, Torebjork HE, Wallin BG: Somatosensory, proprioceptive and sympathetic activity in human peripheral nerves. Physiol Rev 59: 919-57, 1979
13. Snel YE, Brummer RJ, Bol E, Doerga ME, Zelissen PM, Zonderland ML Boer P, Koomans HA, Koppeschaar HP: Direct assessment of extracellular water volume by the bromide-dilution method in growth hormone-deficient adults. Eur J Clin Invest 25: 708-714, 1995
14. Boer P: Estimated lean body mass as an index for normalization of body fluid volumes in humans. Am J Physiol 247: F632-F636, 1984
15. Boer P, Sleumer JH, Spriensma M: Confirmation of the optimal pH for measuring renin activity in plasma. Clin Chem 31: 149-150, 1985
16. Schalekamp MA, Beevers DG, Briggs JD, Brown JJ, Davies DL, Fraser R, Lever AF, Medina A, Morton JJ, Robertson JI, Tree M: Hypertension in chronic renal failure. Am J Med 55: 379-390, 1973
17. Converse RL, Jacobson TN, Toto RD, Jost CMT, Cosentino F, Fouad-Tarazi F, Victor RG: Sympathetic overactivity in patients with chronic renal failure. N Engl J Med 327: 1912-1918, 1992
18. Grassi G, Turri C, Dell'Oro R, Stella ML, Bolla GB, Mancia G: Effect of chronic angiotensin converting enzyme inhibition on sympathetic nerve traffic and baroreflex control of the circulation in essential hypertension. J Hypertens 16: 1789-1796, 1998
19. Grassi G, Cattaneo BM, Seravalle G, Lanfranchi A, Pozi M, Morganti A, Carugo S, Mancia G: Effects of chronic ACE inhibition on sympathetic nerve traffic and baroreflex control of circulation in heart failure. Circulation 96: 1173-1179, 1997
20. Schwieler JH, Hjemdahl P: Influence of angiotensin-converting enzyme inhibition on sympathetic neurotransmission: Possible roles of bradykinin and prostaglandins. J Cardiovasc Pharmacol 20[suppl 9]: S39-S46, 1992
21. Mailloux LU, Haley WE: Hypertension in the ESRD patient: pathophysiology, therapy, outcomes, and future directions. Am J Kidney Dis 32: 705-719, 1998
22. Sica DA, Lo MW, Shaw WC, Keane WF, Gehr TWB, Halstenson CE, Lipschutz K, Furtek CI, Ritter MA, Shahinfar S: The pharmacokinetics of losartan in renal insufficiency. J Hypertens. 13[Suppl 1]: S49-S52, 1995
23. Davies RO, Gomez HJ, Irvin JD, Walker JF: An overview of the clinical pharmacology of enalapril. Br J Clin Pharmacol 18 IS: 215S-229S, 1984
24. Azizi M, Guyene TT, Chatellier G, Wargon M, Ménard J: Additive effects of losartan and enalapril on blood pressure and plasma active renin. Hypertension. 29: 634-640, 1997
25. Mogensen CE, Neldam S, Tikkanen I, Oren S, Viskoper R, Watts RW, Cooper ME for the CALM Study Group: Randomised cotrolled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. B Med J 321: 1440-1444, 2000
26. Vissing SF, Scherrer U, Victor RG: Relation between sympathetic outflow and vascular resistance in the calf during perturbations in central venous pressure. Circ Res 65: 1710-1717, 1989
27. Esler M, Jennings G, Korner P, Blombery P, Sacharias N, Leonard P: Measurement of total and organ specific norepinephrine kinetics in humans. Am J Physiol 245: E21-E28, 1984
28. Sakata K, Shirotani M, Yoshida H, Kurata C: Comparison of effects of enalapril and nitrendipine on cardiac sympathetic nervous system in essential hypertension. J Am Coll Cardiol 32: 438-443, 1998
29. Rump LC: Advantages of Ang II receptor blockade over ACE inhibition with respect to suppression of sympathetic activity: Heartening news for the kidney? Nephrol Dial Tranplant 14: 556-559, 1999
30. Rump LC, Oberhauser V, Schwertfeger E, Schollmeyer P: Experimental evidence to support ELITE. Lancet 351: 644, 1998